Effect of deoxycytidine on the in vitro response of human leukemia cells to inhibitors of de novo pyrimidine biosynthesis.
The effect of high concentrations of exogenous dCyd on the growth inhibitory properties of several inhibitors of de novo pyrimidine biosynthesis (dThd, 3-DAU, PALA, PF) was examined in three cultured human leukemic cell lines (HL-60, K-562, KG-1), and a dCyd kinase-deficient, Ara-C-resistant variant (HL-60/Ara-C). In the presence of dCyd concentrations (10(-3) M), far exceeding normal human plasma levels (0.5 to 4.0 X 10(6) M), substantial but partial reversal of pyrimidine antagonist-mediated growth inhibition and restoration of intracellular dCTP levels was noted in all cell types except HL-60/Ara-C. When high concentrations of dCyd (10(-3) M) were combined with low levels of uridine or cytidine (10(-5) M), full restoration of growth was observed in sensitive cell lines. When exposed to supraphysiologic concentrations of dCyd, HL-60/Ara-C cells were more sensitive to the growth inhibitory effects of pyrimidine antagonists than parent HL-60 cells; this phenomenon was maximal at 10(-4) M dCyd and was not observed in the presence of dCyd concentrations of 10(-6) M or lower. These studies suggest that in the presence of low concentrations of uridine or cytidine, perturbations in intracellular dCTP pools may play a critical role in determining the in vitro antiproliferative response of human leukemic myeloid cells to diverse inhibitors of de novo pyrimidine biosynthesis. They also raise the possibility that modulation of exogenous dCyd concentrations may improve the therapeutic efficacy of pyrimidine antagonists toward certain salvage pathway-deficient, drug-resistant leukemic cells.
D015092:3-Deazauridine / Q000494:pharmacology; D000577:Amides; D001224:Aspartic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line / Q000187:drug effects; D003841:Deoxycytidine / Q000494:pharmacology*; D003842:Deoxycytidine Kinase / Q000172:deficiency; D004347:Drug Interactions; D006801:Humans; D007942:Leukemia, Experimental / Q000378:metabolism*; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D011720:Pyrazoles; D011743:Pyrimidines / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D012263:Ribonucleosides / Q000494:pharmacology; D012266:Ribose; D013936:Thymidine / Q000494:pharmacology
D000577:Amides; D011720:Pyrazoles; D011743:Pyrimidines; D012263:Ribonucleosides; D003841:Deoxycytidine; D015092:3-Deazauridine; D001224:Aspartic Acid; C002997:pyrazofurin; D012266:Ribose; C013195:sparfosic acid; D003842:Deoxycytidine Kinase; D010746:Phosphonoacetic Acid; D013936:Thymidine